Clinical performance of the LMA Protector™ airway in moderately obese patients.

Autor: Shariffuddin II; Department of Anesthesiology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia., Chaw SH; Department of Anesthesiology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia. sh_chaw@yahoo.com., Ng LW; Department of Anesthesiology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia., Lim CH; Department of Anesthesiology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia., Zainal Abidin MF; Department of Anesthesiology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia., Wan Zakaria WA; Department of Anesthesiology, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia., Teoh WH; Wendy Teoh Pte.Ltd, Private Anaesthesia Practice, Singapore, Singapore.
Jazyk: angličtina
Zdroj: BMC anesthesiology [BMC Anesthesiol] 2020 Jul 31; Vol. 20 (1), pp. 184. Date of Electronic Publication: 2020 Jul 31.
DOI: 10.1186/s12871-020-01100-z
Abstrakt: Background: The 4th National Audit Project of The Royal College of Anaesthetists and The Difficult Airway Society (NAP4) reported a higher incidence of supraglottic airway device (SAD) related pulmonary aspiration in obese patients especially with the first-generation SADs. The latest single-use SAD, the Protector™ provides a functional separation of the respiratory and digestive tracts and its laryngeal cuff with two ports allowing additional suction in tandem with the insertion of a gastric tube. The laryngeal cuff of LMA Protector™ allows a large catchment reservoir in the event of gastric content aspiration.
Methods: We evaluated the performance characteristics of the LMA Protector™ in 30 unparalysed, moderately obese patients. First attempt insertion rate, time for insertion, oropharyngeal leak pressure (OLP), and incidence of complications were recorded.
Results: We found high first and second attempt insertion rates of 28(93%) and 1(33%) respectively, with one failed attempt where no capnography trace could be detected, presumably from a downfolded device tip. The LMA Protector™ was inserted rapidly in 21.0(4.0) seconds and demonstrated high OLP of 31.8(5.4) cmH2O. Fibreoptic assessment showed a clear view of vocal cords in 93%. The incidence of blood staining on removal of device was 48%, postoperative sore throat 27%, dysphagia 10% and dysphonia 20% (all self-limiting, resolving a few hours postoperatively).
Conclusions: We conclude that the LMA Protector™ was associated with easy, expedient first attempt insertion success, demonstrating high oropharyngeal pressures and good anatomical position in the moderately obese population, with relatively low postoperative airway morbidity.
Trial Registration: Australian New Zealand Clinical Trials Registry, ACTRN12617001152314 . Registered 7 August 2017.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje